Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026 S4.4.3: prohibited at all times. Non-Specified. [1]
S4.4.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical context and warnings
The Irish Mildronate label describes oral meldonium dihydrate as an adjunct for mild chronic cardiac insufficiency in adults. It cautions about renal and liver disease and interactions with cardiovascular medicines. Reported effects include allergy, headache and digestive symptoms; pregnancy and pediatric evidence are limited. [2]
- A jurisdiction-specific label is not proof that the product is marketed everywhere or a general endorsement of use.
What remains uncertain
- The draft’s treated-cow milk and treated-calf meat reports returned no substantive text in this review. Their experimental exposure findings are not repeated, and ordinary food is not asserted to cause a positive test.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- HPRA Mildronate summary of product characteristics ↗Accessed 2026-11-10 · Relevant document text opened
Relevant cited sections
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.